Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: A population-based nested case-control study

Drug Safety

Volumn 37, Issue 7, 2014, Pages 521-528

  Chou, Hsin Chun ^a   Chen, Wen Wen ^a   Hsiao, Fei Yuan ^b,c  

^a Taiwan Drug Relief Foundation   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CHINESE; CHOLELITHIASIS; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES COMPLICATIONS SEVERITY INDEX; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ACUTE DISEASE; ADOLESCENT; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FACTUAL DATABASE; MIDDLE AGED; PANCREATITIS; RISK; STATISTICAL ANALYSIS; TAIWAN; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; RISK; TAIWAN; YOUNG ADULT;

EID: 84904754605     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0171-x     Document Type: Article

References (31)

1. Scheen A. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf. 2013;12:545-57.
2. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract. 2010;64:984-90.
3. Cohen D. Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. BMJ. 2013;346:f2607.
4. Sue M, Yoshihara A, Kuboki K, Hiroi N, Yoshino G. A case of severe acute necrotizing pancreatitis after administration of sitagliptin. Clin Med Insights Case Rep. 2013;6:23-7.
5. Garg R, Hussey C, Ibrahim S. Pancreatitis associated with the use of sitagliptin and orlistat combination: a case report. Diabet Med. 2010;27:485-6.
6. US Food and Drug Administration. Sitagliptin (marketed as Januvia and Janumet): reports of acute pancreatitis. http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183800.htm. Accessed 16 May 2013.
7. US Food and Drug Administration. Information of healthcare professionals: exenatide (marketed as Byetta) - 8/2008 update. http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm. Accessed 16 May 2013.
8. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019-27.
9. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33:2349-54.
10. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14.
11. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61:1250-62.
12. Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534-9.
13. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab. 2010;12:766-71.
14. Gonzalez-Perez A, Schlienger RG, Rodriguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care. 2010;33:2580-5.
15. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care. 2009;32:834-8.
16. Lai SW, Muo CH, Liao KF, Sung FC, Chen PC. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol. 2011;106:1697-704.
17. Shen HN, Chang YH, Chen HF, Lu CL, Li CY. Increased risk of severe acute pancreatitis in patients with diabetes. Diabet Med. 2012;29:1419-24.
18. Shen HN, Lu CL. Incidence, resource use, and outcome of acute pancreatitis with/without intensive care: a nationwide population-based study in Taiwan. Pancreas. 2011;40:10-5.
19. Hsiao FY, Yang CL, Huang YT, Huang WF. Using Taiwan's national health insurance research databases for pharmacoepidemiology research. J Food Drug Anal. 2007;15:99-108.
20. Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf. 2013;36:643-9.
21. Wen YW, Tsai YW, Huang WF, Hsiao FY, Chen PF. The potentially inappropriate prescription of new drug: thiazolidinediones for patients with type II diabetes in Taiwan. Pharmacoepidemiol Drug Saf. 2011;20:20-9.
22. Hsiao FY, Tsai YW, Wen YW, et al. Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf. 2010;19:786-91.
23. Hsiao FY, Mullins CD. The association between thiazolidinediones and hospitalisation for fracture in type 2 diabetic patients: a Taiwanese population-based nested case-control study. Diabetologia. 2010;53:489-96.
24. Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf. 2009;32:675-90.
25. National Health Insurance Research Database [Internet]. Available from http://w3.nhri.org.tw/nhird//en/index.htm. Accessed 20 Sep 2011.
26. International Classification of Diseases, Ninth Revision (ICD-9). World Health Organization 2011.
27. Moores K, Gilchrist B, Carnahan R, Abrams T. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):194-202.
28. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012;18:721-6.
29. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Predicting costs with diabetes complications severity index in claims data. Am J Manag Care. 2012;18:213-9.
30. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14:15-23.
31. Hamajima N, Hirose K, Inoue M, Takezaki T, Kuroishi T, Tajima K. Case-control studies: matched controls or all available controls? J Clin Epidemiol. 1994;47:971-5. (Pubitemid 24268905)